論文

査読有り 最終著者 責任著者
2021年7月31日

Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome

European Heart Journal
  • Taisuke Ishikawa
  • Hiroki Kimoto
  • Hiroyuki Mishima
  • Kenichiro Yamagata
  • Soshiro Ogata
  • Yoshiyasu Aizawa
  • Kenshi Hayashi
  • Hiroshi Morita
  • Tadashi Nakajima
  • Yukiko Nakano
  • Satoshi Nagase
  • Nobuyuki Murakoshi
  • Shinya Kowase
  • Kimie Ohkubo
  • Takeshi Aiba
  • Shimpei Morimoto
  • Seiko Ohno
  • Shiro Kamakura
  • Akihiko Nogami
  • Masahiko Takagi
  • Matilde Karakachoff
  • Christian Dina
  • Jean-Jacques Schott
  • Koh-Ichiro Yoshiura
  • Minoru Horie
  • Wataru Shimizu
  • Kunihiro Nishimura
  • Kengo Kusano
  • Naomasa Makita
  • 全て表示

42
29
開始ページ
2854
終了ページ
2863
記述言語
掲載種別
研究論文(学術雑誌)
DOI
10.1093/eurheartj/ehab254
出版者・発行元
Oxford University Press (OUP)

<title>Abstract</title>
<sec>
<title>Aims</title>
The prognostic value of genetic variants for predicting lethal arrhythmic events (LAEs) in Brugada syndrome (BrS) remains controversial. We investigated whether the functional curation of SCN5A variations improves prognostic predictability.


</sec>
<sec>
<title>Methods and results</title>
Using a heterologous expression system and whole-cell patch clamping, we functionally characterized 22 variants of unknown significance (VUSs) among 55 SCN5A mutations previously curated using in silico prediction algorithms in the Japanese BrS registry (n = 415). According to the loss-of-function (LOF) properties, SCN5A mutation carriers (n = 60) were divided into two groups: LOF-SCN5A mutations and non-LOF SCN5A variations. Functionally proven LOF-SCN5A mutation carriers (n = 45) showed significantly severer electrocardiographic conduction abnormalities and worse prognosis associated with earlier manifestations of LAEs (7.9%/year) than in silico algorithm-predicted SCN5A carriers (5.1%/year) or all BrS probands (2.5%/year). Notably, non-LOF SCN5A variation carriers (n = 15) exhibited no LAEs during the follow-up period. Multivariate analysis demonstrated that only LOF-SCN5A mutations and a history of aborted cardiac arrest were significant predictors of LAEs. Gene-based association studies using whole-exome sequencing data on another independent SCN5A mutation-negative BrS cohort (n = 288) showed no significant enrichment of rare variants in 16 985 genes including 22 non-SCN5A BrS-associated genes as compared with controls (n = 372). Furthermore, rare variations of non-SCN5A BrS-associated genes did not affect LAE-free survival curves.


</sec>
<sec>
<title>Conclusion</title>
In vitro functional validation is key to classifying the pathogenicity of SCN5A VUSs and for risk stratification of genetic predictors of LAEs. Functionally proven LOF-SCN5A mutations are genetic burdens of sudden death in BrS, but evidence for other BrS-associated genes is elusive.


</sec>

リンク情報
DOI
https://doi.org/10.1093/eurheartj/ehab254
URL
http://academic.oup.com/eurheartj/article-pdf/42/29/2854/39505973/ehab254.pdf
ID情報
  • DOI : 10.1093/eurheartj/ehab254
  • ISSN : 0195-668X
  • eISSN : 1522-9645

エクスポート
BibTeX RIS